Clinical Report: Evaluating Health and Economic Impacts of HCV Initiatives in Jails
Overview
This report evaluates the health benefits, costs, and cost-effectiveness of hepatitis C elimination strategies in jail settings for people who inject drugs. It highlights the potential for jail-based interventions to improve public health outcomes while addressing the financial implications for correctional facilities.
Background
Hepatitis C virus (HCV) remains a significant public health challenge in the U.S., particularly among justice-involved populations. With rising rates of acute HCV infections and a high prevalence of chronic HCV among incarcerated individuals, innovative strategies are essential for achieving national elimination targets. Correctional facilities present unique opportunities for engaging individuals who inject drugs in HCV care, yet face distinct barriers to effective treatment.
Data Highlights
No numerical data available in the source material.
Key Findings
Injection drug use is the primary transmission route for HCV, necessitating targeted strategies.
Carceral settings are critical for reaching and engaging individuals who inject drugs in hepatitis C care.
New care models in California prisons reduced viremia prevalence by 18%.
Jails have higher admission volumes and shorter detention periods, complicating HCV treatment continuity.
Direct-acting antiviral treatments enhance the feasibility of jail-based HCV interventions.
Jail-based HCV elimination efforts could yield broader public health benefits despite financial challenges.
Clinical Implications
Healthcare providers should consider the unique challenges and opportunities presented by jail settings for HCV treatment. Implementing universal opt-out screening and immediate linkage to treatment can facilitate better health outcomes for justice-involved individuals. Continuous care coordination post-release is essential for sustaining treatment success.
Conclusion
Jail-based hepatitis C elimination strategies represent a promising approach to addressing the public health burden of HCV among people who inject drugs. Effective implementation can lead to improved health outcomes and potential cost savings in the long term.
by Lin Zhu, Lora N. Magaldi, Indrani A. Wagh, Eliza R. Ennis, Marissa B. Reitsma, Danica E. Kuncio, Eman Addish, Sandy R. Varghese, Nathan W. Furukawa, Amanda A. Honeycutt, Yijie Chen, Benjamin P. Linas, Joshua A. Salomon
